From the filing about the delay of the 10Q:
State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)
Generex’s acquisition of controlling interests in Olaregen Therapeutix, Inc. and Regentys Corporation near the end of the fiscal quarter ended January 31, 2019 presented consolidation and other accounting issues delaying the preparation and review of the financial statements for the fiscal quarter. Generex anticipates that it will file its Form 10-Q for the period ended January 31, 2019 within the five day extension period provided by Securities Exchange Act Rule 12b-25
The last 10Q was delayed for similar reasons and we wound up getting some very interesting data in the filing.
